Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Geneva Capital Management LLC

Geneva Capital Management LLC lowered its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 2.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,816 shares of the medical research company’s stock after selling 418 shares during the period. Geneva Capital Management LLC’s holdings in Charles River Laboratories International were worth $2,918,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in CRL. Tortoise Investment Management LLC increased its holdings in Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 57 shares in the last quarter. Wolff Wiese Magana LLC acquired a new position in Charles River Laboratories International during the 3rd quarter worth approximately $32,000. Assetmark Inc. boosted its holdings in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after acquiring an additional 173 shares during the period. Headlands Technologies LLC acquired a new stake in Charles River Laboratories International in the first quarter valued at approximately $41,000. Finally, Whittier Trust Co. of Nevada Inc. raised its stake in shares of Charles River Laboratories International by 219.3% during the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 193 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on CRL shares. The Goldman Sachs Group dropped their price target on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating on the stock in a research note on Thursday, August 8th. Evercore ISI increased their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. Bank of America lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating and cut their target price for the company from $250.00 to $215.00 in a research report on Wednesday, October 2nd. TD Cowen raised their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday. Finally, Redburn Atlantic began coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They issued a “sell” rating and a $151.00 price target on the stock. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Charles River Laboratories International has an average rating of “Hold” and an average target price of $217.54.

Charles River Laboratories International Stock Down 2.2 %

NYSE:CRL opened at $215.84 on Wednesday. The firm has a market capitalization of $11.04 billion, a PE ratio of 27.01, a price-to-earnings-growth ratio of 5.70 and a beta of 1.38. Charles River Laboratories International, Inc. has a 52 week low of $168.24 and a 52 week high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The stock has a 50 day moving average of $194.85 and a 200-day moving average of $207.91.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. During the same period last year, the business posted $2.72 earnings per share. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. Analysts predict that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Charles River Laboratories International declared that its Board of Directors has initiated a share buyback plan on Wednesday, August 7th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire up to 9.6% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).